CD19 and B-cell chronic lymphocytic leukemia: Dergis et al. performed the first phase 1/2 trial evaluating third-generation CAR T-cell therapy (HD-CAR-1) targeting CD19 in 9 heavily pretreated patients with RR CLL and B-cell lymphoma (#NCT03676504) [169].